Preservation of endothelium-dependent and Nω-nitro-L-arginine methyl ester- and indomethacin-resistant arterial relaxation in high-cholesterol-diet fed rabbits by treatment with fluvastatin, an HMG-CoA reductase inhibitor

Journal of Cardiovascular Pharmacology

Volumn 42, Issue 1, 2003, Pages 55-62

  Mitani, Hironobu ^a,b   Kimura, Masaaki ^a  

^a Tsukuba Research Institute   (Japan)

^b NOVARTIS PHARMA K K   (Japan)

Author keywords

Acetylcholine; Endothelium dependent hyperpolarizing factor; Fluvastatin; Hypercholesterolemia; Nitric oxide; Rabbits

Indexed keywords

ACETYLCHOLINE; CALCIMYCIN; CHOLESTEROL; ENDOTHELIUM DERIVED HYPERPOLARIZING FACTOR; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOMETACIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G) NITRO DEXTRO ARGININE METHYL ESTER; NITRIC OXIDE; NITROPRUSSIDE SODIUM;

ANIMAL MODEL; ARTERY DILATATION; ARTICLE; BLOOD VESSEL REACTIVITY; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFECT; FEMORAL ARTERY; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; THORACIC AORTA;

ACETYLCHOLINE; ANIMALS; AORTA, THORACIC; CALCIMYCIN; CHOLESTEROL; CHOLESTEROL, DIETARY; DIET; ENDOTHELIUM, VASCULAR; FATTY ACIDS, MONOUNSATURATED; FEMORAL ARTERY; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INDOLES; INDOMETHACIN; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; RABBITS; VASCULAR RESISTANCE; VASODILATION;

EID: 0037716346     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200307000-00009     Document Type: Article

References (48)

1. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-526.
2. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002-2012.
3. Moncada S, Herman AG, Higgs EA, et al. Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res. 1977;11:323-344.
4. Chen G, Suzuki H, Weston AH. Acetylcholine releases endothelium-derived hyperpolarizing factor and EDRF from rat blood vessels. Br J Pharmacol. 1988;95:1165-1174.
5. Chen GF, Suzuki H. Calcium dependency of the endothelium-dependent hyperpolarization in smooth muscle cells of the rabbit carotid artery. J Physiol. 1990;421:521-534.
6. Komori K, Vanhoutte PM. Endothelium-derived hyperpolarizing factor. Blood Vessels. 1990;27:238-245.
7. Mombouli JV, Vanhoutte PM. Endothelium-derived hyperpolarizing factor(s): updating the unknown. Trends Pharmacol Sci. 1997;18:252-256.
8. Hecker M, Bara AT, Bauersachs J, et al. Characterization of endothelium-derived hyperpolarizing factor as a cytochrome P450-derived arachidonic acid metabolite in mammals. J Physiol. 1994;481:407-414.
9. Campbell WB, Gebremedhin D, Pratt PF, et al. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 1996;78:415-423.
10. Randall MD, Alexander SP, Bennett T, et al. An endogenous cannabinoid as an endothelium-derived vasorelaxant. Biochem Biophys Res Commun. 1996;229:114-120.
11. Edwards G, Dora KA, Gardener MJ, et al. K+ is an endothelium-derived hyperpolarizing factor in rat arteries. Nature. 1998;396:269-272.
12. Cohen RA, Plane F, Najibi S, et al. Nitric oxide is the mediator of both endothelium-dependent relaxation and hyperpolarization of the rabbit carotid artery. Proc Natl Acad Sci U S A. 1997;94:4193-4198.
13. Tare M, Parkington HC, Coleman HA, et al. Hyperpolarization and relaxation of arterial smooth muscle caused by nitric oxide derived from the endothelium. Nature. 1990;346:69-71.
14. Fujii K, Tominaga M, Ohmori S, et al. Decreased endothelium-dependent hyperpolarization to acetylcholine in smooth muscle of the mesenteric artery of spontaneously hypertensive rats. Circ Res. 1992;70:660-669.
15. Cowan CL, Steffen RP. Lysophosphatidylcholine inhibits relaxation of rabbit abdominal aorta mediated by endothelium-derived nitric oxide and endothelium-derived hyperpolarizing factor independent of protein kinase C activation. Arterioscler Thromb Vasc Biol. 1995;15:2290-2297.
16. Endo K, Abiru T, Machida H, et al. Endothelium-derived hyperpolarizing factor does not contribute to the decrease in endothelium-dependent relaxation in the aorta of streptozotocin-induced diabetic rats. Gen Pharmacol. 1995;26:149-153.
17. Mantelli L, Amerini S, Ledda F. Roles of nitric oxide and endothelium-derived hyperpolarizing factor in vasorelaxant effect of acetylcholine as influenced by aging and hypertension. J Cardiovasc Pharmacol. 1995;25:595-602.
18. Urakami-Harasawa L, Shimokawa H, Nakashima M, et al. Importance of endothelium-derived hyperpolarizing factor in human arteries. J Clin Invest. 1997;100:2793-2799.
19. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
20. Herd JA. The lipoprotein and coronary atherosclerosis study (LCAS): lipid and metabolic factors related to atheroma and clinical events. Am J Med. 1998;104:42S-49S.
21. Mitani H, Bandoh T, Ishikawa J, et al. Inhibitory effects of fluvastatin, a new HMG-CoA reductase inhibitor, on the increase in vascular ACE activity in cholesterol-fed rabbits. Br J Pharmacol. 1996;119:1269-1275.
22. Bandoh T, Mitani H, Niihashi M, et al. Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition. J Cardiovasc Pharmacol. 2000;35:136-144.
23. Kitagawa S, Yamaguchi Y, Kunitomo M, et al. NG-nitro-L-arginine-resistant endothelium-dependent relaxation induced by acetylcholine in the rabbit renal artery. Life Sci. 1994;55:491-498.
24. Dong H, Waldron GJ, Galipeau D, et al. NO/PGI2-independent vasorelaxation and the cytochrome P450 pathway in rabbit carotid artery. Br J Pharmacol. 1997;120:695-701.
25. Lamontagne D, Konig A, Bassenge E, et al. Prostacyclin and nitric oxide contribute to the vasodilator action of acetylcholine and bradykinin in the intact rabbit coronary bed. J Cardiovasc Pharmacol. 1992;20:652-657.
26. Mitani H, Bandoh T, Kimura M, et al. Increased activity of vascular ACE related to atherosclerotic lesions in hyperlipidemic rabbits. Am J Physiol. 1996;271:H1065-H1071.
27. Shiomi M, Shiraishi M, Yata T, et al. Effect of fluvastatin sodium on secretion of very low density lipoprotein and serum cholesterol levels. In vivo study using low density lipoprotein receptor deficient watanabe heritable hyperlipidemic rabbits. Arzneimittelforschung. 1994;44:1154-1156.
28. Tomita H, Egashira K, Kubo-Inoue M, et al. Inhibition of NO synthesis induces inflammatory changes and monocyte chemoattractant protein-1 expression in rat hearts and vessels. Arterioscler Thromb Vasc Biol. 1998;18:1456-1464.
29. Kanazawa K, Kawashima S, Mikami S, et al. Endothelial constitutive nitric oxide synthase protein and mRNA increased in rabbit atherosclerotic aorta despite impaired endothelium-dependent vascular relaxation. Am J Pathol. 1996;148:1949-1956.
30. Pervin S, Singh R, Rosenfeld ME, et al. Estradiol suppresses MCP-1 expression In vivo: implications for atherosclerosis. Arterioscler Thromb Vasc Biol. 1998;18:1575-1582.
31. Sumi D, Hayashi T, Thakur NK, et al. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects - the relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. Atherosclerosis. 2001;155:347-357.
32. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A. 1998;95:8880-8885.
33. Kano H, Hayashi T, Sumi D, et al. A HMG-CoA reductase inhibitor improved regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: possible relevance of up-regulation of endothelial NO synthase mRNA. Biochem Biophys Res Commun. 1999;259:414-419.
34. Alfon J, Guasch JF, Berrozpe M, et al. Nitric oxide synthase II (NOS II) gene expression correlates with atherosclerotic intimal thickening. Preventive effects of HMG-CoA reductase inhibitors. Atherosclerosis. 1999;145:325-331.
35. Verbeuren TJ, Bonhomme E, Laubie M, et al. Evidence for induction of nonendothelial NO synthase in aortas of cholesterol-fed rabbits. J Cardiovasc Pharmacol. 1993;21:841-845.
36. Hibbs JB Jr, Taintor RR, Vavrin Z, et al. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun. 1988;157:87-94.
37. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem. 1994;269:4705-4708.
38. Cowan CL, Palacino JJ, Najibi S, et al. Potassium channel-mediated relaxation to acetylcholine in rabbit arteries. J Pharmacol Exp Ther. 1993;266:1482-1489.
39. Kwon SC, Pyun WB, Park GY, et al. The involvement of K+ channels and the possible pathway of EDHF in the rabbit femoral artery. Yonsei Med J. 1999;40:331-338.
40. Ghanam K, Ea-Kim L, Javellaud J, et al. Involvement of potassium channels in the protective effect of 17beta-estradiol on hypercholesterolemic rabbit carotid artery. Atheroselerosis. 2000;152:59-67.
41. Honda H, Moroe H, Fujii H, et al. Short term hypercholesterolemia alters N(G)-nitro-L-arginine- and indomethacin-resistant endothelium-dependent relaxation by acetylcholine in rabbit renal artery. Jpn J Pharmacol. 2001;85:203-206.
42. Brandes RP, Behra A, Lebherz C, et al. N(G)-nitro-L-arginine- and indomethacin-resistant endothelium-dependent relaxation in the rabbit renal artery: effect of hypercholesterolemia. Atherosclerosis. 1997;135:49-55.
43. Galle J, Busse R, Bassenge E. Hypercholesterolemia and atherosclerosis change vascular reactivity in rabbits by different mechanisms. Arterioscler Thromb. 1991;11:1712-1718.
44. Brandes RP, Behra A, Lebherz C, et al. Lovastatin maintains nitric oxide but not EDHF-mediated endothelium-dependent relaxation in the hypercholesterolemic rabbit carotid artery. Atherosclerosis. 1999;142:97-104.
45. Parthasarathy S, Steinbrecher UP, Barnett J, et al. Essential role of phospholipase A2 activity in endothelial cell-induced modification of low density lipoprotein. Proc Natl Acad Sci USA. 1985;82:3000-3004.
46. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993;91:2546-2551.
47. Taketomi T, Hara A, Uemura K, et al. Effect of long-term treatment with sulfatide on hyperlipidemia and progression of atherosclerosis in WHHL rabbits. Jpn J Exp Med. 1989;59:221-231.
48. Rikitake Y, Kawashima S, Takeshita S, et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 2001;154:87-96.